Quick Links

Email Alerts


Email Address	*

Mailing Lists *
Releases SEC Filings Presentation Events

2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005

12/09/2022 Opexa Therapeutics to Present at the Oppenheimer 22nd Annual Healthcare Conference

11/14/2011 Opexa Announces Publication in Multiple Sclerosis Journal of Tovaxin® Phase IIb Clinical Trial Results

11/11/2021 Opexa Therapeutics to Present at the Lazard Capital Markets 8th Annual Healthcare Conference

11/08/2022 Opexa's Tovaxin® for the Treatment of Multiple Sclerosis Granted Fast Track Designation by FDA

11/04/2022 Opexa Therapeutics Reports Third Quarter 2011 Financial Results and Provides Corporate Update

11/02/2022 Opexa Elects Gail Maderis to Board of Directors

09/19/2011 Opexa’s CEO Invited to Present at Two Cell Therapy Forums in Asia During September, 2011

09/12/2021 Dr. Mark Freedman to Join Opexa's Scientific Advisory Board

08/11/2021 Opexa Therapeutics Reports Second Quarter 2011 Financial Results and Provides Corporate Update

06/28/2011 Opexa Executes Service Agreement with Blood Group Alliance, Inc.

06/02/2022 Opexa Initiates Discussions with Health Canada in Pre-CTA Meeting

05/17/2011 Opexa Executes Strategic Service Agreement with the American Red Cross

05/06/2022 Opexa Therapeutics Reports First Quarter 2011 Financial Results

04/15/2011 Opexa Presents Tovaxin® Data at American Academy of Neurology 2011 Annual Meeting

03/23/2011 Opexa to Present Tovaxin® Data at 2011 American Academy of Neurology Annual Meeting

03/08/2022 Opexa Therapeutics Reports Year End 2010 Financial Results and Provides Corporate Update

02/22/2011 Opexa CEO Invited as Keynote Speaker at Cell Therapy Conference in Beijing, China

02/09/2022 Opexa to Present at the 13th Annual BIO CEO & Investor Conference on February 14, 2022

02/08/2022 Opexa Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants

02/07/2022 Opexa Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants